Lay Abstract
Autism Spectrum Disorders (Autism) are thought to be relatively common, with analyses estimating 1-2% in the population could meet diagnostic criteria. There is debate over whether the number of new cases is rising, with some suggesting an increase, whilst other studies finding no change. In this study we take anonymised healthcare record data from more than 3.6 million people in Wales to produce a national estimate of prevalence and incidence. We found the overall prevalence rate of autism in the population was 0.51%. The number of new-recorded cases of autism increased from 0.19% per 1000 person-years in 2001 to 0.64% per 1000 person-years in 2016. The estimate of 0.51% prevalence in the population is lower than suggested by previous studies, potentially due to underdiagnosis or lack of recognition by services. From 2000-2016 the number of autism services for adults has increased, and autism is more widely known in society. We suggest that these extra services and awareness have contributed to the 3.4-fold rise in new autism diagnoses over the study and the >150% increase in the years 2008-2016. Our study suggests that while the number of people being diagnosed with autism is increasing, many are still missed by healthcare services.
Competing Interest Statement
JH has received grants from Takeda for research work unrelated to this project. The other authors declare no competing interests.
Funding Statement
This project was funded by a Wellcome Trust ISSF Clinical Primer award, and subsequent Wellcome Trust GW4-CAT Clinical Doctoral Fellowship to JFGU. JH and JFGU are supported by Healthcare Research Wales through the National Centre for Mental Health (NCMH) and an MRC Pathfinder Grant (MC_PC_17212). MDPB and AJ are supported by Healthcare Research Wales (grants CA04 and SC35296), and an MRC Pathfinder Grant (MC_PC_17211).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data access was approved by the SAIL independent Information Governance Review Panel in 2018 (application 0843). The policies, permissions, processes, structures and controls applied to manage the SAIL databank are described elsewhere (John et al., 2018).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data referred to is held within the SAIL Databank and governed by data access approval systems.
